BioMarin Pharmaceuticals Inc (BMRN): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

BioMarin Pharmaceuticals (BMRN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole was unchanged today. By the end of trading, BioMarin Pharmaceuticals rose 81 cents (2%) to $41.68 on average volume. Throughout the day, 1.4 million shares of BioMarin Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock ranged in a price between $40.62-$41.72 after having opened the day at $40.90 as compared to the previous trading day's close of $40.87. Other companies within the Drugs industry that increased today were: XenoPort (XNPT), up 15.3%, Theratechnologies (THER), up 15.2%, Delcath Systems (DCTH), up 13.7%, and Oxygen Biotherapeutics (OXBT), up 11.4%.

• ACTIVE STOCK TRADERS: Get full access to Jim Cramer's thoughts for less than $3/week - sometimes before he says them on TV! Start with a 14-Day Free Trial.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and rest of the world. BioMarin Pharmaceuticals has a market cap of $5.03 billion and is part of the health care sector. Shares are up 18.9% year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate BioMarin Pharmaceuticals a buy, no analysts rate it a sell, and four rate it a hold.

TheStreet Ratings rates BioMarin Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

• You can view the full BioMarin Ratings Report.

On the negative front, Cell Therapeutics (CTIC), down 24.9%, Geron Corporation (GERN), down 11.3%, AEterna Zentaris (AEZS), down 11.1%, and Tianyin Pharmaceutical (TPI), down 10.5%, were all laggards within the drugs industry with Arena Pharmaceuticals (ARNA) being today's drugs industry laggard.

• Use our drugs section to find industry-relevant news.
• Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF (XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech (BIS).

• Find other investment ideas from our top rated ETFs lists.

FREE from Real Money's Jim Cramer: Winners and Losers Election 2012 - Steps to take NOW so you can profit no matter who is in charge! Free download now.

 

For more information on Biomarin Pharmaceutical Inc. click any of the following:

• Biomarin Pharmaceutical Inc. Stock Price

• Biomarin Pharmaceutical Inc. Analyst Ratings

• Biomarin Pharmaceutical Inc. Key Stats & Profile

• Biomarin Pharmaceutical Inc. Earnings

• Biomarin Pharmaceutical Inc. Ratio Comparison

• Biomarin Pharmaceutical Inc. Growth Rates

• Biomarin Pharmaceutical Inc. Balance Sheet

• Biomarin Pharmaceutical Inc. Cash Flow

• Biomarin Pharmaceutical Inc. Income Statement